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reporting a case of donor cell leukemia (DCL) occurring in a patient who previously underwent cord blood (CB) transplantation for myelodysplastic syndrome and describing the clinical and biological differences between DCL arising after hematopoietic SCT (HSCT) from either CB or BM sources. We would like to comment on these issues, reporting an unusual case of DCL in a patient with a long history of acute promyelocytic leukemia (APL).
A 45-year-old man presented in December 2004 with intermediate-risk APL, positive for t(15;17), resulting in the PML-RARA chimeric transcript. He achieved hematologic CR with a remission induction cycle including all-trans retinoic acid (ATRA) and idarubicin. He subsequently underwent three consolidation chemotherapy cycles. Molecular CR was obtained at the end of the consolidation treatment in May 2005. Two months later, the patient exhibited molecular relapse, so that he underwent salvage chemotherapy with ATRA, cytarabine and mitoxantrone, reaching a second molecular CR. The patient was subsequently treated with an allogeneic peripheral blood (PB) HSCT from his HLA-identical male sibling (donor 1), with myeloablative conditioning (BU 12.8 mg/kg in 4 days and CY 120 mg/kg in 2 days). Short-term MTX and CyA therapy was used as GVHD prophylaxis. Full donor 1 chimerism was obtained by day +59, as assessed by PCR-based analysis of autosomal short tandem repeats (microsatellites) on DNA samples extracted from BM cells. Unfortunately, in February 2008, the patient experienced another molecular recurrence, initially treated with DLIs and, then, with arsenic trioxide, resulting in molecular CR for the third time. Then, he underwent a second allogeneic transplantation from another HLA-identical 52-year-old male sibling (donor 2), using BM as the stem cell source. On this occasion, the conditioning regimen consisted of TBI (800 cGy), fludarabine 120 mg/m 2 in 4 days, CY 80 mg/kg in 2 days and ATG 40 mg/kg/day for 2 days. Short-term MTX and CyA were administered as GVHD prophylaxis. The patient became a full chimera of donor 2 on day +30, did not experience significant post-transplant complications and had a 5-year disease-free interval. In July 2013, fever, asthenia, weight loss and multiple superficial adenopathies occurred. The complete blood count (CBC) showed pancytopenia (WBC 1.0 × 10 9 /L, Hb 10 g/dL, Plt 11 × 10 9 /L) in the absence of coagulopathy. The differential count documented 22% neutrophil, 69% lymphocytes, 5% myelocytes, 1% metamyelocytes and 3% agranular blasts. Either morphologic APL relapse or the occurrence of therapy-related myeloid neoplasm was initially suspected. Surprisingly, BM aspirate and trephine biopsy examinations demonstrated >90% B-lymphoid blasts. A complex karyotype was observed on cytogenetic analysis. The presence of either PML-RARA or BCR-ABL fusion transcripts was excluded. Unexpectedly, the microsatellite analysis showed full chimera donor 2, thus diagnosing B-ALL of donor origin. The patient was treated with combination chemotherapy (VCR, idarubicin, CY and dexamethasone), but failed to achieve remission. In detail, BM aplasia was initially documented, with a subsequent rapid increase of BM blast count (70%). Therefore, he has been enrolled in phase II protocol based on the use of blinatumomab, an antibody BiTE anti-CD19. At the time of publication, he is in hematologic CR, with a normal CBC, after two cycles.
HSCT may be complicated by either disease relapse or development of secondary malignancies. The occurrence of leukemia or myelodysplasia from donor cells is recognized as a rare, but probably underestimated complication, especially those with a lymphoid phenotype. [1] [2] [3] Since the first description of this usually aggressive disorder in 1971, several other cases have been reported, 4 with a variable incidence ranging from 0.13 to 5% in HSCT recipients. 1 To the best of our knowledge, we have reported the first case of DCL with lymphoid phenotype in a patient with a previous APL diagnosis, who has needed two HSCTs from different male sibling donors, and from different stem cells sources, namely PB and BM. Three DCL cases arising after two HSCTs, in patients with either aplastic anemia or Fanconi anemia, have previously been reported in the literature [5] [6] [7] (Table 1) . Of note, in only one case HSCT was performed from two different donors and, contrary to our case, the leukemic cells were of first donor derivation. 5 Furthermore, DCL in patients with a previous APL has only anecdotally been reported 8, 9 (Table 2) . In both cases, AML developed, 26 months and 17 years after HSCT, respectively. 8, 9 . Our DCL case is unusual because it developed from donor 2 cells, after a long interval (5 years) and with the uncommon B-lymphoid phenotype.
The causative mechanisms of DCL remain speculative and include sustained antigenic stimulation, defective immune surveillance and replication stress due to proliferation demand. 4, 8 BM irradiation and repeated cytotoxic treatments are also implicated as possible contributing factors in the development of DCL, through the induction of alterations in the BM stroma/microenvironment. 4, 10 Therefore, in our case, profound immunosuppression, DNA damage and impairment of DNA repair mechanisms induced by chemotherapy and irradiation may also have contributed to create an aberrant BM microenvironment in which the malignant clone from donor 2 may have developed and progressively gained a proliferative advantage over normal cells. This hypothesis could be endorsed in our case by the long latency (5 years) between HSCT and the occurrence of DCL and the acquisition of a complex karyotype. Of note, the median duration between BMT and the occurrence of DCL has been reported to be 36 months (range 2-312 months). 1 In conclusion, DCL may be under-diagnosed and frequently unexpected in patients suspected of having leukemia relapse after HSCT. Accurate molecular examinations, especially of chimerism by microsatellites, are essential to investigate the donor origin of leukemic cells, mainly in the cases in which a leukemic cell lineage, different from initial diagnosis, is found or when more than one HSCT has been performed. Further cytogenetic and molecular studies of DCL-associated genomic alterations may help to elucidate the 'multi-hit' mechanism that underlies leukemogenesis, in order to try to prevent its development in HSCT recipients. Abbreviations: AA = aplastic anemia; CC = conventional cytogenetics; CT = chemotherapy; DCL = donor cell leukemia; D1 = donor 1; D2 = donor 2; FA = Fanconi anemia; HSCT = hematopoietic SCT; MDS = myelodysplastic syndrome; mo = months; MSC = mesenchymal stem cell; MUD = mismatched unrelated donor; NA = not available; R = recipient; Sib = sibling; STR = short tandem repeats; VNTR = variable number of tandem repeats. Abbreviations: APL = acute promyelocytic leukemia; CT = chemotherapy; D = donor; DCL = donor cell leukemia; HSCT = hematopoietic SCT; mo = months; NA = not available; PB = peripheral blood; R = recipient; Sib = sibling; STR = short tandem repeats.
